Literature DB >> 34296614

Targeting Nanoparticles to Bioengineered Human Vascular Networks.

Kathleen Cullion1,2, Laura C Petishnok1,2, Hyunji Koo1,2, Brendan Harty1,3, Juan M Melero-Martin4, Daniel S Kohane1,3.   

Abstract

Pharmacotherapy of vascular anomalies has limited efficacy and potentially limiting toxicity. Targeted nanoparticle (NP) drug delivery systems have the potential to accumulate within tissues where the vasculature is impaired, potentially leading to high drug levels (increased efficacy) in the diseased tissue and less in off-target sites (less toxicity). Here, we investigate whether NPs can be used to enhance drug delivery to bioengineered human vascular networks (hVNs) that are a model of human vascular anomalies. We demonstrate that intravenously injected phototargeted NPs enhanced accumulation of NPs and the drug within hVNs. With phototargeting we demonstrate 17 times more NP accumulation within hVNs than was detected in hVNs without phototargeting. With phototargeting there was 10-fold more NP accumulation within hVNs than in any other organ. Phototargeting resulted in a 6-fold increase in drug accumulation (doxorubicin) within hVNs in comparison to animals injected with the free drug. Nanoparticulate approaches have the potential to markedly improve drug delivery to vascular anomalies.

Entities:  

Keywords:  bioengineered human vascular network; micelle; phototargeted nanoparticle; tissue engineering; vascular anomalies

Mesh:

Substances:

Year:  2021        PMID: 34296614      PMCID: PMC8719414          DOI: 10.1021/acs.nanolett.1c02027

Source DB:  PubMed          Journal:  Nano Lett        ISSN: 1530-6984            Impact factor:   12.262


  31 in total

1.  Sclerotherapy of craniofacial venous malformations: complications and results.

Authors:  B Berenguer; P E Burrows; D Zurakowski; J B Mulliken
Journal:  Plast Reconstr Surg       Date:  1999-07       Impact factor: 4.730

Review 2.  Vascularization is the key challenge in tissue engineering.

Authors:  Esther C Novosel; Claudia Kleinhans; Petra J Kluger
Journal:  Adv Drug Deliv Rev       Date:  2011-03-17       Impact factor: 15.470

Review 3.  Late sequelae and long-term outcomes of vascular anomalies.

Authors:  Denise M Adams; Steven J Fishman
Journal:  Semin Pediatr Surg       Date:  2017-09-09       Impact factor: 2.754

4.  Transdermal regulation of vascular network bioengineering using a photopolymerizable methacrylated gelatin hydrogel.

Authors:  Ruei-Zeng Lin; Ying-Chieh Chen; Rafael Moreno-Luna; Ali Khademhosseini; Juan M Melero-Martin
Journal:  Biomaterials       Date:  2013-06-14       Impact factor: 12.479

5.  Coumarin-caged glycine that can be photolyzed within 3 microseconds by visible light.

Authors:  Vishakha R Shembekar; Yongli Chen; Barry K Carpenter; George P Hess
Journal:  Biochemistry       Date:  2007-04-11       Impact factor: 3.162

6.  Bioengineering human microvascular networks in immunodeficient mice.

Authors:  Ruei-Zeng Lin; Juan M Melero-Martin
Journal:  J Vis Exp       Date:  2011-07-11       Impact factor: 1.355

Review 7.  Cell-Penetrating Peptides-Mechanisms of Cellular Uptake and Generation of Delivery Systems.

Authors:  Sara Trabulo; Ana Luísa Cardoso; Miguel Mano; Maria C Pedroso De Lima
Journal:  Pharmaceuticals (Basel)       Date:  2010-03-30

Review 8.  Targeted Delivery of Bioactive Molecules for Vascular Intervention and Tissue Engineering.

Authors:  Hannah A Strobel; Elisabet I Qendro; Eben Alsberg; Marsha W Rolle
Journal:  Front Pharmacol       Date:  2018-11-21       Impact factor: 5.810

9.  Intravenous treatment of choroidal neovascularization by photo-targeted nanoparticles.

Authors:  Yanfei Wang; Chi-Hsiu Liu; Tianjiao Ji; Manisha Mehta; Weiping Wang; Elizabeth Marino; Jing Chen; Daniel S Kohane
Journal:  Nat Commun       Date:  2019-02-18       Impact factor: 14.919

10.  Effect of wavelength and beam width on penetration in light-tissue interaction using computational methods.

Authors:  Caerwyn Ash; Michael Dubec; Kelvin Donne; Tim Bashford
Journal:  Lasers Med Sci       Date:  2017-09-12       Impact factor: 3.161

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.